In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
Massachusetts, USA-based clinical-stage CNS biotech EIP Pharma has entered a definitive all-stock merger agreement with Diffusion Pharmaceuticals forming a publicly traded company, sending the latter’s share up 5% pre-market. 30 March 2023
Generics
The expiration of the patent for palbociclib, a leading anti-breast cancer drug, in India has opened up new opportunities for generic versions of the drug. The Indian government highlighted this development in Parliament and intensely discussed the endless possibilities that could arise from the availability of generic palbociclib and other similar generic oncology drugs, reports The Pharma Letter’s India correspondent. 30 March 2023
Biotechnology
Belgian G-protein coupled receptor (GPCR) company Confo Therapeutics revealed today that it has entered a collaboration agreement with Japan’s Daiichi Sankyo for the discovery and development of small molecule agonists against an undisclosed target associated with CNS diseases. 30 March 2023
Biotechnology
The US Food and Drug Administration (FDA) has lifted a partial clinical hold on the Phase I/II VELA trial of BLU-222, said the drugs developer, Blueprint Medicines, sending the US biotech’s shares up 4% to $42.57. 30 March 2023
Pharmaceutical
US healthcare giant Johnson & Johnson has made the bold move of halting its investigational respiratory syncytial virus (RSV) adult vaccine program and discontinuing its Phase III EVERGREEN study. 30 March 2023
Biotechnology
Ireland-headquartered biotech Horizon Therapeutics today announced that the Italian medicines regulator, the AIFA, has approved the reimbursement of inebilizumab for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD). 30 March 2023
Biotechnology
A short delay to bluebird bio’s US regulatory submission for lovo-cel (lovotibeglogene autotemcel) appears to have spooked investors, with shares in the company falling by a quarter. 30 March 2023
Biotechnology
New Jersey, USA-based cancer giant Merck has converted a conditional nod for its checkpoint blocker, Keytruda (pembrolizumab), into regular approval. 30 March 2023
Generics
After announcing the start of discussions early last year relating to its cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis (PrEP), ViiV Healthcare, which is majority-owned by UK pharma major GSK, says an accord has now been struck with the Medicines Patent Pool (MPP). 30 March 2023
Biotechnology
US biotech firm Aridis Pharmaceuticals today revealed via a filing with the Securities and Exchange Commission (SEC) that it has received written notice from MedImmune, the global biologics R&D arm of Anglo-Swedish pharma major AstraZeneca, that it has terminated certain license agreement by and between MedImmune and the company dated as of July 12, 2021. 29 March 2023
Pharmaceutical
Théa Open Innovation (TOI) and Galimedix Therapeutics have announced the signing of a licensing agreement. 29 March 2023
Pharmaceutical
Danish diabetes care giant Novo Nordisk has announced it is terminating supplies of its Ozempic (semaglutide) to Russia at the end of the current year. 29 March 2023
Pharmaceutical
Privately-held German drugmaker Boehringer Ingelheim reported a rise of 17% in its net sales for 2022 compared to the prior year. 29 March 2023
Biotechnology
The European Commission (EC) has approved Libtayo (cemiplimab) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with ≥1% PD-L1 expression, US biotech firm Regeneron revealed today. 29 March 2023
Pharmaceutical
Karen Harrison has been named chief operating officer of the Therapeutics Division at Avacta, a UK-based life sciences company developing targeted oncology drugs and diagnostics. 29 March 2023
Biotechnology
Shares US biotech Bicycle Therapeutics closed up more than 11% at $22.40 yesterday, after it revealed a licensing deal that could earn it as much as $1.7 billion. 29 March 2023
Biotechnology
Results presented at the Society of Gynecologic Oncology (SGO) annual meeting have put two PD-1 inhibitors on course for a battle in the advanced endometrial cancer space. 29 March 2023
Pharmaceutical
US clinical-stage biopharma company Viking Therapeutics saw its shares close up nearly 70% at $15.44 yesterday, after it released encouraging early-stage data on its obesity candidate VK2735. 29 March 2023
Pharmaceutical
Intra-Cellular Therapies has announced positive top-line results from its Study 403, testing the novel depression therapy lumateperone. 29 March 2023
Pharmaceutical
Covant Therapeutics, a Boston, USA-based covalent drug discovery company that was incubated by Roivant Sciences, has entered into an exclusive research collaboration and worldwide licensing agreement with German family-owned pharma major Boehringer Ingelheim covering Covant’s ADAR1 program. 29 March 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze